Computing limits on medicine risks based on collections of individual case reports.

Area of Science:

• Pharmacovigilance
• Drug safety assessment
• Quantitative risk analysis

Background:

• Quantifying medicine risks, especially for rare adverse effects, is challenging after market release.
• Individual case reports are vital for detecting adverse effects but not typically used for risk quantification.
• Accurate risk quantification is crucial for assessing a therapeutic agent's overall value.

Purpose of the Study:

• To demonstrate a method for computing medicine risk limits from individual case reports.
• To enable risk quantification in situations where it is otherwise difficult or impossible.

Main Methods:

• A model was developed where drug exposures can lead to adverse episodes, with each report corresponding to one episode.
• Derived upper and lower limits for the per-exposure risk of an adverse effect for a specific drug.
• Utilized reporting ratios and total exposure data to compute risk limits.

Main Results:

• An upper risk limit was derived using the reporting ratio of a drug and adverse effect, under specific assumptions about reporting frequency.
• A lower risk limit was calculated by dividing reports of a drug-adverse effect pair by total exposures.
• Computed risk limits for narcolepsy post-Pandemrix and coeliac disease post-antihypertensive treatment, aligning with epidemiological data.

Conclusions:

• The proposed framework allows for the quantification of medicine risks, particularly useful for rare adverse effects.
• This method enhances structured benefit-risk assessments in pharmacovigilance.
• Applicable in scenarios where traditional risk quantification methods are insufficient.